Latest Health News

EcoGraf Limited has advanced its vertically integrated battery anode materials business with a US$105 million financing mandate for its Epanko Graphite Mine and positive momentum in US and EU government support.

Centuria Capital No. 2 Fund confirms full compliance with note terms and stable loan positions in its Q4 FY25 report, reassuring investors amid a steady operational quarter.

Biotron Limited has successfully raised $1.27 million through an entitlement issue to fund its antiviral drug development, including a promising Hepatitis B compound that cleared its initial animal safety study.

N1 Holdings reports a profitable FY2025 with strategic expansion into Australia's largest aggregator panel and launches AI-driven credit tools to enhance SME lending operations.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

Minbos Resources has secured key financing and made significant construction strides on its Angolan phosphate fertilizer plant, while rolling out promising new fertilizer blends to support local agriculture.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Careteq Limited reports a significant reduction in operating cash outflow and modest revenue growth for FY25, while facing delays in its key platform integration and a dispute with the ATO over R&D claims.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.